内部人交易雷达

美国 · SEC Form 4 · 快照日期： 2026-10-18 · 构建时间： 2026-10-18 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

Zoetis Inc.

ZTS · NYSE · CIK 0001555280 · Healthcare · Drug Manufacturers—Specialty & Generic

内部人信号

68.6 / 100

3 位买方 · 3 条买入交易行 · $886.4K 买入总额

为什么有这个信号？

买方广度中等
买入规模中等
角色较强
近期性较低
确信度较强
评分构成

每条进度条表示其对当前分数的贡献；权重和公式保持不变。

Cluster+21.0 / 35
买入规模+16.9 / 25
角色+20.0 / 20
近期性+0.7 / 10
确信度+10.0 / 10

哪些因素限制了当前分数？

  • ⚠ Cluster breadth is moderate · 3 insider(s), not 4+
  • ⚠ Purchase activity is becoming less recent
  • ✓ 角色得分高 · 买入者中职位最高的是：Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct
MCCALLISTER MICHAEL BDirector
●○
DAMELIO FRANK ADirector
●○
Esch KevinExecutive Vice President
○○
FULLER JULIEExecutive Vice President
○○
Stetter MarkDirector
○
PARENT LOUISE MDirector
○
● 买入▼ 卖出○ 其他

Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.

买方广度与集中度

合资格买方3
买入集中度57%最大买方： DAMELIO FRANK A · $501.3K
聚集买入 · 15天3 insiders峰值活动： 2026-05-11–2026-05-13

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

68.6 / 100

最新留档分数

→ +0.0 pts相对上一个留档快照
  1. 68.7
  2. 68.8
  3. 68.7
  4. 68.6
  5. 68.6

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

近期 Form 4 活动

3买入
2卖出
79其他 Form 4 交易行
38SEC 申报 · 365天
买入3 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他9 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M
+2.7%
3M
-0.8%
6M
-36.5%
12M
-47.9%

波动率与流动性

波动率
32.4%
Beta
—
平均每日成交额
USD 404.8M

估值

市值
USD 30.9B
P/E
11.6×

基本面

利润率
28.2%
ROE
78.3%
细分行业
Drug Manufacturers—Specialty & Generic

市场数据

价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, P/E, 利润率, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-07-31 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数
18,424,459
上期报告
17,390,071
日均成交量
4,504,058
回补天数
4.1

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-05-13DAMELIO FRANK A买入 (P)Common Stock6,650USD 75.39USD 501,344SEC 申报 ↗
2026-05-13Bisaro Paul买入 (P)Common Stock2,000USD 75.88USD 151,760SEC 申报 ↗
2026-05-11MCCALLISTER MICHAEL B买入 (P)Common Stock3,000USD 77.76USD 233,280SEC 申报 ↗
2021-02-19SCULLY ROBERT W买入 (P)Common Stock7,590USD 164.68USD 1,249,931SEC 申报 ↗

Form 4 申报证据

84 transaction lines in the latest 365-day window; 694 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-09-30FULLER JULIE期权行权／转换 (M)Common Stock799USD —USD —SEC 申报 ↗
2026-09-30FULLER JULIE代扣税 (F)Common Stock274USD 69.83USD 19,133SEC 申报 ↗
2026-08-07DAMELIO FRANK A赠与 (G)Common Stock6,650USD 0.00USD 0SEC 申报 ↗
展开近期 Form 4 证据 (30 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-09-30FULLER JULIE期权行权／转换 (M)Common Stock799USD —USD —SEC 申报 ↗
2026-09-30FULLER JULIE代扣税 (F)Common Stock274USD 69.83USD 19,133SEC 申报 ↗
2026-08-07DAMELIO FRANK A赠与 (G)Common Stock6,650USD 0.00USD 0SEC 申报 ↗
2026-06-10MCCALLISTER MICHAEL B赠与 (G)Common Stock1,209USD 0.00USD 0SEC 申报 ↗
2026-05-21Stetter Mark期权行权／转换 (M)Common Stock1,572USD —USD —SEC 申报 ↗
2026-05-20PARENT LOUISE M期权行权／转换 (M)Common Stock12,130USD —USD —SEC 申报 ↗
2026-05-13DAMELIO FRANK A买入 (P)Common Stock6,650USD 75.39USD 501,344SEC 申报 ↗
2026-05-13Bisaro Paul买入 (P)Common Stock2,000USD 75.88USD 151,760SEC 申报 ↗
2026-05-11MCCALLISTER MICHAEL B买入 (P)Common Stock3,000USD 77.76USD 233,280SEC 申报 ↗
2026-04-30Esch Kevin期权行权／转换 (M)Common Stock259USD —USD —SEC 申报 ↗
2026-04-30Esch Kevin代扣税 (F)Common Stock75USD 114.97USD 8,623SEC 申报 ↗
2026-03-09Norden Gregory赠与 (G)Common Stock1,213USD 0.00USD 0SEC 申报 ↗
2026-02-19Sarbaugh Keith期权行权／转换 (M)Common Stock386USD —USD —SEC 申报 ↗
2026-02-19Sarbaugh Keith代扣税 (F)Common Stock154USD 127.28USD 19,601SEC 申报 ↗
2026-02-19Reed Willie M期权行权／转换 (M)Common Stock1,619USD —USD —SEC 申报 ↗
2026-02-19PECK KRISTIN C期权行权／转换 (M)Common Stock7,354USD —USD —SEC 申报 ↗
2026-02-19PECK KRISTIN C代扣税 (F)Common Stock3,623USD 127.28USD 461,135SEC 申报 ↗
2026-02-19PARENT LOUISE M期权行权／转换 (M)Common Stock1,619USD —USD —SEC 申报 ↗
2026-02-19PARENT LOUISE MJ (J)Common Stock615USD 127.28USD 78,277SEC 申报 ↗
2026-02-19Norden Gregory期权行权／转换 (M)Common Stock1,619USD —USD —SEC 申报 ↗
2026-02-19Norden GregoryJ (J)Common Stock406USD 127.28USD 51,676SEC 申报 ↗
2026-02-19MCCALLISTER MICHAEL B期权行权／转换 (M)Common Stock1,619USD —USD —SEC 申报 ↗
2026-02-19MCCALLISTER MICHAEL BJ (J)Common Stock413USD 127.28USD 52,567SEC 申报 ↗
2026-02-19Leatherberry Antoinette Renee期权行权／转换 (M)Common Stock1,619USD —USD —SEC 申报 ↗
2026-02-19Leatherberry Antoinette ReneeJ (J)Common Stock406USD 127.28USD 51,676SEC 申报 ↗
2026-02-19Lagano Roxanne期权行权／转换 (M)Common Stock750USD —USD —SEC 申报 ↗
2026-02-19Lagano Roxanne代扣税 (F)Common Stock258USD 127.28USD 32,838SEC 申报 ↗
2026-02-19Joseph Wetteny期权行权／转换 (M)Common Stock2,050USD —USD —SEC 申报 ↗
2026-02-19Joseph Wetteny代扣税 (F)Common Stock703USD 127.28USD 89,478SEC 申报 ↗
2026-02-19Hattersley Gavin期权行权／转换 (M)Common Stock1,619USD —USD —SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-18
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码ZTS
CIK0001555280
行业Healthcare
细分行业Drug Manufacturers—Specialty & Generic Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
交易所NYSE

数据覆盖

本地 Form 4 历史694 transaction lines from 2020-01-15 to 2026-09-30
6 P purchase lines · 141 S sale lines · 547 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.